Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project
| Authors | |
|---|---|
| Year of publication | 2025 |
| Type | Peer-reviewed scientific article |
| Magazine / Source | CLINICAL GENITOURINARY CANCER |
| MU Faculty or unit | |
| Citation | |
| web | https://www.sciencedirect.com/science/article/abs/pii/S1558767325000825 |
| Doi | https://doi.org/10.1016/j.clgc.2025.102382 |
| Keywords | First-line therapy; Real world outcomes; Renal cancer; Tyrosine kinase inhibitors |
| Description | The treatment of metastatic renal cell carcinoma (RCC) has changed in the last years, with different options available, and with no data comparing these new therapies. In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data is comparable with what has been seen in randomised trials, considering the bias present in RWO studies. Introduction: The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically in the last few years, with different options being available, and with no data comparing these new systemic therapies. Therefore, the value of real-world outcomes (RWO) becomes of great interest to understand the effectiveness of these treatments. Here we analyze the outcome of metastatic RCC patients treated with first-line cabozantinib in a retrospective cohort from the Czech Republic and Poland Methods: Patients with metastatic RCC treated with first-line cabozantinib in the Czech Republic and Poland were included in a retrospective fashion. Data were collected regarding progression-free survival (PFS), overall survival (OS), response rate and toxicity, with a focus in several subgroups of interest. Results: We identified 146 patients, the majority of them (80.8%) with clear cell RCC (ccRCC). The median OS was 14.7 months, and the median PFS 8.2 months, with a response rate of 30.3%. CTCAE v3.0 grade 3 + 4 toxicity was presented in 34.2% of patients. The efficacy of Cabozantinib was maintained regardless of histologic subtype and the presence of sarcomatoid component, although PFS and OS data were numerically better for nonclear cell RCC. Bone and liver metastases were confirmed as independent factor for poor survival in the multivariate analysis. Conclusions: In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data can be considered comparable with what has been seen in randomised clinical trials, considering the inherent bias present in RWO studies. |
| Related projects: |